Peptidream Announces Pre-Clinical Results Of Oral Il-17A And Il-17F Inhibitor

Reuters
2025.12.17 13:21
Dec 17 (Reuters) - PeptiDream Inc (4587.T) : * PEPTIDREAM ANNOUNCES PROMISING PRE-CLINICAL RESULTS OF PROPRIETARY ORAL IL-17A AND IL-17F DUAL INHIBITOR WITH BIOLOGIC-LIKE EFFICACY FOR THE TREATMENT OF PSORIASIS Source text: Further company coverage: (4587.T)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer